A short perspective on the long road to effective treatments for Alzheimer's disease

Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of pharmacology Vol. 176; no. 18; pp. 3636 - 3648
Main Author Reynolds, David S.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.09.2019
John Wiley and Sons Inc
Subjects
Aging
Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Alzheimer's disease
Amyloid beta-Peptides - metabolism
Animals
Dementia
Dementia disorders
Humans
Neurodegenerative diseases
Precision medicine
Review
Risk factors
Themed Section: Review
Online AccessGet full text

Cover

Abstract Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living with AD is set to rise dramatically over the coming decades. There are currently no disease‐modifying treatments for AD, and the few symptomatic agents available have limited impact on the disease. Perhaps surprisingly, there is relatively little activity in the AD research and development field compared with other diseases with a high mortality burden, such as cancer. There is enormous economic incentive to discover and develop the first disease‐modifying treatment, but previous failure has significantly reduced further industrial investment in this field. The short review looks at the historical path trodden to develop treatments and reflects on the journey down the road to truly effective treatments for people living with AD. Linked Articles This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc
AbstractList Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living with AD is set to rise dramatically over the coming decades. There are currently no disease‐modifying treatments for AD, and the few symptomatic agents available have limited impact on the disease. Perhaps surprisingly, there is relatively little activity in the AD research and development field compared with other diseases with a high mortality burden, such as cancer. There is enormous economic incentive to discover and develop the first disease‐modifying treatment, but previous failure has significantly reduced further industrial investment in this field. The short review looks at the historical path trodden to develop treatments and reflects on the journey down the road to truly effective treatments for people living with AD. Linked Articles This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc
Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living with AD is set to rise dramatically over the coming decades. There are currently no disease‐modifying treatments for AD, and the few symptomatic agents available have limited impact on the disease. Perhaps surprisingly, there is relatively little activity in the AD research and development field compared with other diseases with a high mortality burden, such as cancer. There is enormous economic incentive to discover and develop the first disease‐modifying treatment, but previous failure has significantly reduced further industrial investment in this field. The short review looks at the historical path trodden to develop treatments and reflects on the journey down the road to truly effective treatments for people living with AD.Linked ArticlesThis article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc
Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living with AD is set to rise dramatically over the coming decades. There are currently no disease-modifying treatments for AD, and the few symptomatic agents available have limited impact on the disease. Perhaps surprisingly, there is relatively little activity in the AD research and development field compared with other diseases with a high mortality burden, such as cancer. There is enormous economic incentive to discover and develop the first disease-modifying treatment, but previous failure has significantly reduced further industrial investment in this field. The short review looks at the historical path trodden to develop treatments and reflects on the journey down the road to truly effective treatments for people living with AD. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living with AD is set to rise dramatically over the coming decades. There are currently no disease-modifying treatments for AD, and the few symptomatic agents available have limited impact on the disease. Perhaps surprisingly, there is relatively little activity in the AD research and development field compared with other diseases with a high mortality burden, such as cancer. There is enormous economic incentive to discover and develop the first disease-modifying treatment, but previous failure has significantly reduced further industrial investment in this field. The short review looks at the historical path trodden to develop treatments and reflects on the journey down the road to truly effective treatments for people living with AD. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single biggest risk factor for the vast majority of sporadic AD cases, and because the world's population is aging, the number of people living with AD is set to rise dramatically over the coming decades. There are currently no disease-modifying treatments for AD, and the few symptomatic agents available have limited impact on the disease. Perhaps surprisingly, there is relatively little activity in the AD research and development field compared with other diseases with a high mortality burden, such as cancer. There is enormous economic incentive to discover and develop the first disease-modifying treatment, but previous failure has significantly reduced further industrial investment in this field. The short review looks at the historical path trodden to develop treatments and reflects on the journey down the road to truly effective treatments for people living with AD. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
Author Reynolds, David S.
AuthorAffiliation 1 Research & Policy Alzheimer's Research UK Cambridge UK
AuthorAffiliation_xml – name: 1 Research & Policy Alzheimer's Research UK Cambridge UK
Author_xml – sequence: 1
  givenname: David S.
  orcidid: 0000-0002-5461-3166
  surname: Reynolds
  fullname: Reynolds, David S.
  email: david.reynolds@alzheimersresearchuk.org
  organization: Alzheimer's Research UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30657599$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1P3DAYhK0KVBbaQ_9AZamH0kPAduKPXCotCAoSUnugZ8vxviFGSZza3kXw6zHsgigCX3yYZ0Zjzy7aGv0ICH2h5IDmc9hM3QGtuKIf0IxWUhS8VHQLzQghsqBUqR20G-M1IVmU_CPaKYngktf1DF3Ocex8SHiCECewya0A-xGnDnDvxyscvFng5DG07UZNAUwaYEwRtz7geX_XgRsgfI944SKYCJ_Qdmv6CJ839x76e3pyeXxWXPz-dX48vyhsVZW0aFiubAQDIWRtRC1MYwmnVkpGG0mM4sI2hhrKW2BMtYI1quK2LYltJNiq3EM_17nTshlgYXOnYHo9BTeYcKu9cfp_ZXSdvvIrLSTlvBY5YH8TEPy_JcSkBxct9L0ZwS-jZlTWpSJclBn99gq99ssw5udpxmrBalVWMlNfXzZ6rvL04Rk4XAM2-BgDtNq6ZJLzDwVdrynRD5PqPKl-nDQ7frxyPIW-xW7Sb1wPt--D-ujP2dpxD49EsBY
CitedBy_id crossref_primary_10_1002_prot_25978
crossref_primary_10_3390_biomedicines10050985
crossref_primary_10_1080_01924788_2023_2172900
crossref_primary_10_1186_s12929_023_00939_x
crossref_primary_10_1186_s40035_023_00394_6
crossref_primary_10_2174_1381612828666220608093639
crossref_primary_10_2147_IJN_S305851
crossref_primary_10_1016_j_neulet_2023_137332
crossref_primary_10_3389_fphar_2023_1056402
crossref_primary_10_3390_molecules26247660
crossref_primary_10_3390_pharmaceutics13091397
crossref_primary_10_1002_alz_14038
crossref_primary_10_2174_1570159X19666210121163224
crossref_primary_10_3233_JAD_210234
crossref_primary_10_1111_bph_14767
crossref_primary_10_1038_s41598_019_56463_2
crossref_primary_10_1159_000511506
crossref_primary_10_31083_j_fbl2711318
Cites_doi 10.1016/j.trci.2018.03.009
10.1016/S1474-4422(03)00530-1
10.1097/NEN.0b013e31825018f7
10.1038/nrd3505
10.1016/j.cell.2017.07.004
10.1002/ana.410380515
10.1016/0022-510X(70)90063-8
10.1159/000354370
10.1586/14737175.2014.945522
10.1096/fj.06-6463fje
10.1038/31508
10.1136/jnnp.66.2.137
10.1038/nrneurol.2015.177
10.1038/ng0694-180
10.1073/pnas.97.4.1456
10.1073/pnas.1301175110
10.3389/fphys.2012.00008
10.1016/j.neuropharm.2018.01.028
10.1186/s13195-017-0318-y
10.1186/s13195-017-0283-5
10.1038/emboj.2012.79
10.1038/349704a0
10.1038/415462a
10.1073/pnas.95.13.7737
10.1016/j.nicl.2013.02.006
10.1073/pnas.72.5.1858
10.1038/nature19323
10.1038/nature24016
10.1056/NEJMoa1706441
10.1212/WNL.0000000000000596
10.1002/ana.20592
10.1038/990107
10.1016/0165-6147(91)90609-V
10.1016/S0196-9781(02)00261-9
10.1016/j.neuron.2013.10.009
10.1093/nar/gkx1121
10.1016/B978-0-444-63380-4.00003-2
10.1016/S0140-6736(08)61075-2
10.1016/j.trci.2018.01.003
10.1038/nrneurol.2009.218
10.1038/nrn2786
10.1056/NEJMoa1312889
10.1111/bph.13877
10.1056/NEJMoa1304839
10.1038/990114
10.1016/j.jalz.2016.02.002
10.1038/ncb1901
10.1212/WNL.0000000000005550
10.1212/WNL.42.3.631
10.1016/j.jalz.2015.06.1893
10.2174/156720509787602852
10.1111/joim.12816
10.1111/bph.13878
10.1111/bph.13882
10.1016/S0140-6736(10)61349-9
10.1001/jama.1997.03540340059034
10.1093/brain/awv055
10.1074/jbc.M114.589069
10.1038/nrn785
10.1016/S0140-6736(13)62426-5
10.1111/nan.12213
10.1038/nm.4397
10.3233/JAD-170062
10.1073/pnas.092136199
10.1006/mcne.1999.0811
10.1073/pnas.90.5.1977
10.1016/j.pneurobio.2007.02.001
10.1056/NEJMoa1705971
10.1038/375754a0
10.1016/j.neuron.2008.04.010
10.1016/j.jalz.2013.03.007
10.1016/j.neurol.2013.07.017
10.1126/science.286.5440.735
10.3389/fneur.2018.00625
10.1007/s004150050299
10.1093/embo-reports/kvf124
10.1016/j.neuron.2014.10.038
10.1101/cshperspect.a006312
10.1016/S0140-6736(76)91936-X
10.1016/S0024-3205(01)01232-2
10.1038/nrn3887
10.1126/science.1072994
10.1126/scitranslmed.3007941
10.1093/brain/awq277
10.1111/j.1471-4159.2011.07476.x
10.1126/science.8346443
10.1126/scitranslmed.aad9704
10.1523/JNEUROSCI.5221-09.2010
10.1038/nature25456
10.1038/ng1197-263
10.1016/j.neuron.2013.12.003
10.1021/acs.jmedchem.6b00307
10.1101/cshperspect.a024539
10.1038/emboj.2010.167
10.1016/S1474-4422(16)30291-5
10.1007/s00401-017-1709-7
10.1016/j.jalz.2010.03.007
10.1001/archneur.60.12.1696
10.2165/00002512-200118110-00006
10.2967/jnumed.114.143347
10.1038/22124
10.1038/nrd1958
10.1097/NEN.0b013e31824b211b
10.1111/bph.13879
10.3389/fnmol.2016.00161
10.1186/s12916-014-0206-2
10.1001/jama.1997.03550160069041
10.1007/s00259-015-3228-x
10.1517/14740338.3.5.425
10.1021/acs.jmedchem.5b01960
10.1016/j.cell.2015.12.056
10.1038/nm840
10.1016/j.neuron.2010.10.013
10.1126/science.7058341
10.1096/fj.02-0394fje
10.1002/ana.21509
10.1001/archneurol.2011.1538
10.1126/science.290.5489.150
10.1016/j.jalz.2017.06.2266
10.2174/1573406413666171002120847
10.1016/j.ejrad.2017.07.014
10.1016/S0021-9258(17)38495-8
10.1111/jnc.12715
10.1002/14651858.CD005593
10.1038/nature11283
10.1016/j.biopsych.2017.08.010
10.1016/j.jalz.2014.08.105
10.1523/JNEUROSCI.14-04-02313.1994
10.1586/14737175.2015.995638
10.1007/s40336-018-0290-y
10.1056/NEJMoa1210951
10.1016/S0140-6736(86)92134-3
10.1007/s13311-014-0295-9
10.1523/JNEUROSCI.16-18-05795.1996
10.1038/ng.3916
10.1016/S1474-4422(12)70015-7
ContentType Journal Article
Copyright 2019 The British Pharmacological Society
2019 The British Pharmacological Society.
Copyright_xml – notice: 2019 The British Pharmacological Society
– notice: 2019 The British Pharmacological Society.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
K9.
NAPCQ
7X8
5PM
DOI 10.1111/bph.14581
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList
ProQuest Health & Medical Complete (Alumni)
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Reynolds
EISSN 1476-5381
EndPage 3648
ExternalDocumentID PMC6715596
30657599
10_1111_bph_14581
BPH14581
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
.3N
.55
.GJ
05W
0R~
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
3V.
4.4
52U
52V
53G
5GY
6J9
7RV
7X7
8-0
8-1
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
8UM
A00
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCUV
ABDBF
ABPVW
ABQWH
ABUWG
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFKRA
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
B0M
BAFTC
BAWUL
BBNVY
BENPR
BFHJK
BHBCM
BHPHI
BKEYQ
BMXJE
BPHCQ
BRXPI
BVXVI
C45
CAG
CCPQU
COF
CS3
DCZOG
DIK
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
ECV
EJD
EMB
EMK
EMOBN
ENC
ESX
EX3
F5P
FUBAC
FYUFA
G-S
GODZA
GX1
H.X
HCIFZ
HGLYW
HMCUK
HYE
HZ~
J5H
KBYEO
LATKE
LEEKS
LH4
LITHE
LK8
LOXES
LSO
LUTES
LW6
LYRES
M1P
M7P
MEWTI
MK0
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N9A
NAPCQ
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P4E
PQQKQ
PROAC
PSQYO
Q.N
Q2X
QB0
RIG
ROL
RPM
RWI
SJN
SUPJJ
SV3
TEORI
TR2
TUS
UKHRP
UPT
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WVDHM
WXSBR
X7M
XV2
Y6R
YHG
ZGI
ZXP
ZZTAW
~8M
~S-
AAFWJ
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
PHGZM
PHGZT
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7QP
7TK
K9.
7X8
5PM
ID FETCH-LOGICAL-c4431-b2581a62e6679a696abc051c7721b70a856cba1a15fe228f62b845cf30cb7ec43
ISSN 0007-1188
1476-5381
IngestDate Thu Aug 21 14:09:41 EDT 2025
Fri Jul 11 13:26:22 EDT 2025
Fri Jul 25 19:11:38 EDT 2025
Mon Jul 21 06:02:44 EDT 2025
Thu Apr 24 23:01:28 EDT 2025
Tue Jul 01 03:00:38 EDT 2025
Wed Jan 22 16:38:51 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Language English
License 2019 The British Pharmacological Society.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4431-b2581a62e6679a696abc051c7721b70a856cba1a15fe228f62b845cf30cb7ec43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-5461-3166
OpenAccessLink https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bph.14581
PMID 30657599
PQID 2296298347
PQPubID 42104
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6715596
proquest_miscellaneous_2179380563
proquest_journals_2296298347
pubmed_primary_30657599
crossref_citationtrail_10_1111_bph_14581
crossref_primary_10_1111_bph_14581
wiley_primary_10_1111_bph_14581_BPH14581
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2019
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: September 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: Hoboken
PublicationTitle British journal of pharmacology
PublicationTitleAlternate Br J Pharmacol
PublicationYear 2019
Publisher Blackwell Publishing Ltd
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley and Sons Inc
References 1997; 278
2018; 284
2010; 11
2012; 120
2013; 3
2013; 2
1991; 12
1995; 38
2013; 369
1997; 277
2002; 99
2004; 3
1999; 286
2014; 370
1995; 375
2012; 488
2014; 130
2012; 11
1998; 393
2013; 9
2018; 46
2009; 11
2018; 6
2018; 9
1986; 2
2006; 20
2018; 4
2015; 138
2010; 29
2000; 97
2016; 43
2014; 14
1985; 95
2013; 110
1992; 42
1991; 349
1998; 95
2014; 12
2010; 30
2010; 6
2014; 11
2011; 377
1976; 2
2008; 58
2002; 415
1970; 11
2002; 3
2017; 134
1996; 16
2016; 164
2012; 31
2016; 12
2017; 549
2017; 58
1984; 2
2013; 80
2018; 90
1994; 14
2007; 82
2008; 372
2016; 8
2018; 14
2017; 7
2017; 49
2013; 169
2011; 10
2003; 17
1999; 246
1999; 400
2018; 83
1999; 402
2017; 9
2000; 290
2012; 71
2010; 68
2015; 41
2018; 378
2018; 136
1986; 261
1999; 14
2003; 9
1997; 17
1982; 215
2008; 64
2001; 18
2012; 69
2014; 6
1998; 55
2014; 55
2014; 53
2014; 289
2015; 15
2015; 16
2018d
2018c
2002; 297
2018b
2018a
2015; 11
2017; 23
2017; 170
1999; 66
2006; 5
2006
1993; 261
2017; 174
2013; 382
1993; 90
2014; 84
2014; 83
1993; 149
2016; 59
2001; 69
1975; 72
2017; 94
2012; 2
2012; 3
2016; 537
2017; 16
2002; 23
2017; 13
2018; 554
2010; 133
2018
2016
2009; 6
2015
1999; 155
2018e
2003; 60
1994; 7
2005; 58
e_1_2_8_26_1
e_1_2_8_49_1
e_1_2_8_68_1
Brion J.‐P. (e_1_2_8_23_1) 1985; 95
e_1_2_8_132_1
e_1_2_8_5_1
Sahakian B. J. (e_1_2_8_116_1) 1993; 149
e_1_2_8_151_1
e_1_2_8_9_1
e_1_2_8_117_1
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_64_1
e_1_2_8_87_1
e_1_2_8_113_1
e_1_2_8_136_1
e_1_2_8_41_1
e_1_2_8_60_1
e_1_2_8_83_1
e_1_2_8_19_1
e_1_2_8_109_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_57_1
e_1_2_8_120_1
e_1_2_8_143_1
e_1_2_8_91_1
e_1_2_8_95_1
e_1_2_8_99_1
e_1_2_8_105_1
e_1_2_8_128_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_53_1
e_1_2_8_76_1
e_1_2_8_101_1
e_1_2_8_124_1
e_1_2_8_147_1
e_1_2_8_30_1
e_1_2_8_72_1
e_1_2_8_29_1
e_1_2_8_25_1
e_1_2_8_48_1
e_1_2_8_2_1
e_1_2_8_133_1
e_1_2_8_110_1
e_1_2_8_152_1
e_1_2_8_6_1
McShane R. (e_1_2_8_94_1) 2006
e_1_2_8_21_1
e_1_2_8_67_1
e_1_2_8_44_1
e_1_2_8_86_1
e_1_2_8_118_1
e_1_2_8_63_1
e_1_2_8_137_1
e_1_2_8_40_1
e_1_2_8_82_1
e_1_2_8_114_1
e_1_2_8_18_1
e_1_2_8_14_1
e_1_2_8_37_1
e_1_2_8_79_1
e_1_2_8_144_1
e_1_2_8_90_1
e_1_2_8_121_1
e_1_2_8_98_1
e_1_2_8_140_1
e_1_2_8_10_1
e_1_2_8_56_1
e_1_2_8_106_1
e_1_2_8_33_1
e_1_2_8_75_1
e_1_2_8_129_1
e_1_2_8_52_1
e_1_2_8_102_1
e_1_2_8_148_1
e_1_2_8_71_1
e_1_2_8_125_1
e_1_2_8_28_1
e_1_2_8_24_1
e_1_2_8_47_1
e_1_2_8_3_1
e_1_2_8_81_1
e_1_2_8_111_1
e_1_2_8_130_1
e_1_2_8_153_1
e_1_2_8_7_1
e_1_2_8_20_1
e_1_2_8_43_1
e_1_2_8_66_1
e_1_2_8_89_1
e_1_2_8_119_1
e_1_2_8_138_1
e_1_2_8_62_1
e_1_2_8_85_1
e_1_2_8_115_1
e_1_2_8_134_1
e_1_2_8_17_1
Glenner G. G. (e_1_2_8_58_1) 1984; 2
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_59_1
e_1_2_8_70_1
e_1_2_8_122_1
e_1_2_8_141_1
e_1_2_8_97_1
Fox N. C. (e_1_2_8_50_1) 1999; 155
e_1_2_8_32_1
e_1_2_8_55_1
e_1_2_8_78_1
e_1_2_8_107_1
e_1_2_8_149_1
e_1_2_8_51_1
e_1_2_8_74_1
e_1_2_8_103_1
e_1_2_8_126_1
e_1_2_8_145_1
e_1_2_8_93_1
e_1_2_8_46_1
e_1_2_8_27_1
e_1_2_8_69_1
e_1_2_8_80_1
e_1_2_8_4_1
e_1_2_8_131_1
e_1_2_8_150_1
e_1_2_8_8_1
e_1_2_8_42_1
e_1_2_8_88_1
e_1_2_8_65_1
e_1_2_8_139_1
e_1_2_8_84_1
e_1_2_8_112_1
e_1_2_8_61_1
e_1_2_8_135_1
e_1_2_8_39_1
e_1_2_8_35_1
e_1_2_8_16_1
e_1_2_8_92_1
e_1_2_8_96_1
e_1_2_8_100_1
e_1_2_8_142_1
e_1_2_8_31_1
e_1_2_8_77_1
e_1_2_8_127_1
e_1_2_8_12_1
e_1_2_8_54_1
e_1_2_8_108_1
e_1_2_8_73_1
e_1_2_8_123_1
e_1_2_8_104_1
e_1_2_8_146_1
References_xml – volume: 90
  start-page: 1977
  year: 1993
  end-page: 1981
  article-title: Apolipoprotein E: High‐avidity binding to beta‐amyloid and increased frequency of type 4 allele in late‐onset familial Alzheimer disease
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 12
  start-page: 56
  year: 2016
  end-page: 61
  article-title: CAP—Advancing the evaluation of preclinical Alzheimer disease treatments
  publication-title: Nature Reviews Neurology
– volume: 43
  start-page: 374
  year: 2016
  end-page: 385
  article-title: Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer's disease: A systematic review and meta‐analysis
  publication-title: European Journal of Nuclear Medicine and Molecular Imaging
– volume: 83
  start-page: 311
  year: 2018
  end-page: 319
  article-title: Anti‐amyloid‐β monoclonal antibodies for Alzheimer's disease: Pitfalls and promise
  publication-title: Biological Psychiatry
– volume: 10
  start-page: 698
  year: 2011
  end-page: 712
  article-title: The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics
  publication-title: Nature Reviews. Drug Discovery
– year: 2018a
– volume: 14
  start-page: 973
  year: 2014
  end-page: 986
  article-title: Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease
  publication-title: Expert Review of Neurotherapeutics
– volume: 382
  start-page: 1968
  year: 2013
  end-page: 1969
  article-title: The G8 Dementia Research Summit—A starter for eight?
  publication-title: Lancet
– volume: 2
  start-page: 421
  year: 1986
  end-page: 426
  article-title: Defective brain microtubule assembly in Alzheimer's disease
  publication-title: Lancet
– volume: 9
  start-page: 60
  year: 2017
  article-title: On the path to 2025: Understanding the Alzheimer's disease continuum
  publication-title: Alzheimers. Res. Ther.
– volume: 23
  start-page: 2223
  year: 2002
  end-page: 2226
  article-title: Passage of amyloid β protein antibody across the blood‐brain barrier in a mouse model of Alzheimer's disease
  publication-title: Peptides
– volume: 174
  start-page: S272
  issue: S1
  year: 2017
  end-page: S359
  article-title: The Concise Guide to PHARMACOLOGY 2017/18: Enzymes
  publication-title: British Journal of Pharmacology
– volume: 133
  start-page: 3336
  year: 2010
  end-page: 3348
  article-title: Brain beta‐amyloid measures and magnetic resonance imaging atrophy both predict time‐to‐progression from mild cognitive impairment to Alzheimer's disease
  publication-title: Brain
– volume: 12
  start-page: 206
  year: 2014
  article-title: The overlap between vascular disease and Alzheimer's disease—Lessons from pathology
  publication-title: BMC Medicine
– volume: 372
  start-page: 216
  year: 2008
  end-page: 223
  article-title: Long‐term effects of Aβ42 immunisation in Alzheimer's disease: Follow‐up of a randomised, placebo‐controlled phase I trial
  publication-title: Lancet
– volume: 149
  start-page: 29
  year: 1993
  end-page: 35
  article-title: Tetrahydroaminoacridine (THA) in Alzheimer's disease: An assessment of attentional and mnemonic function using CANTAB
  publication-title: Acta Neurologica Scandinavica. Supplementum
– volume: 6
  start-page: 99
  year: 2010
  end-page: 107
  article-title: The secretases: Enzymes with therapeutic potential in Alzheimer disease
  publication-title: Nature Reviews. Neurology
– volume: 554
  start-page: 249
  year: 2018
  end-page: 254
  article-title: High performance plasma amyloid‐β biomarkers for Alzheimer's disease
  publication-title: Nature
– volume: 3
  start-page: 688
  year: 2002
  end-page: 694
  article-title: A gamma‐secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish
  publication-title: EMBO Reports
– volume: 400
  start-page: 173
  year: 1999
  end-page: 177
  article-title: Immunization with amyloid‐β attenuates Alzheimer‐disease‐like pathology in the PDAPP mouse
  publication-title: Nature
– volume: 94
  start-page: 16
  year: 2017
  end-page: 24
  article-title: The diagnostic value of FDG and amyloid PET in Alzheimer's disease—A systematic review
  publication-title: European Journal of Radiology
– volume: 6
  start-page: 202
  year: 2010
  end-page: 211.e7
  article-title: The Alzheimer's disease neuroimaging initiative: Progress report and future plans
  publication-title: Alzheimer's & Dementia
– volume: 82
  start-page: 11
  year: 2007
  end-page: 32
  article-title: Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts
  publication-title: Progress in Neurobiology
– volume: 370
  start-page: 322
  year: 2014
  end-page: 333
  article-title: Two phase 3 trials of bapineuzumab in mild‐to‐moderate Alzheimer's disease
  publication-title: The New England Journal of Medicine
– volume: 174
  start-page: S17
  issue: S1
  year: 2017
  end-page: S129
  article-title: The Concise Guide to PHARMACOLOGY 2017/18: G protein‐coupled receptors
  publication-title: British Journal of Pharmacology
– volume: 261
  start-page: 6084
  year: 1986
  end-page: 6089
  article-title: Microtubule‐associated protein tau. A component of Alzheimer paired helical filaments
  publication-title: The Journal of Biological Chemistry
– volume: 393
  start-page: 702
  year: 1998
  end-page: 705
  article-title: Association of missense and 5′‐splice‐site mutations in tau with the inherited dementia FTDP‐17
  publication-title: Nature
– volume: 130
  start-page: 4
  year: 2014
  end-page: 28
  article-title: Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects
  publication-title: Journal of Neurochemistry
– volume: 378
  start-page: 1691
  year: 2018
  end-page: 1703
  article-title: Randomized trial of verubecestat for mild‐to‐moderate Alzheimer's disease
  publication-title: The New England Journal of Medicine
– volume: 84
  start-page: 608
  year: 2014
  end-page: 622
  article-title: The evolution of preclinical Alzheimer's disease: Implications for prevention trials
  publication-title: Neuron
– volume: 95
  start-page: 229
  year: 1985
  end-page: 235
  article-title: Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer
  publication-title: Archives of Biology (Liege)
– volume: 17
  start-page: 263
  year: 1997
  end-page: 264
  article-title: Lack of apolipoprotein E dramatically reduces amyloid β‐peptide deposition
  publication-title: Nature Genetics
– volume: 31
  start-page: 2261
  year: 2012
  end-page: 2274
  article-title: The mechanism of γ‐secretase dysfunction in familial Alzheimer disease
  publication-title: The EMBO Journal
– volume: 284
  start-page: 643
  year: 2018
  end-page: 663
  article-title: Biomarkers for Alzheimer's disease: Current status and prospects for the future
  publication-title: Journal of Internal Medicine
– volume: 11
  start-page: 732
  year: 2014
  end-page: 737
  article-title: Genetics of Alzheimer's disease
  publication-title: Neurotherapeutics
– volume: 290
  start-page: 150
  year: 2000
  end-page: 153
  article-title: Structure of the protease domain of memapsin 2 (β‐secretase) complexed with inhibitor
  publication-title: Science
– volume: 83
  start-page: 253
  year: 2014
  end-page: 260
  article-title: Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta‐analysis
  publication-title: Neurology
– volume: 14
  start-page: 34
  year: 2018
  end-page: 43
  article-title: New perspectives of Alzheimer disease diagnosis—The most popular and future methods
  publication-title: Medicinal Chemistry
– volume: 6
  start-page: 305
  year: 2018
  end-page: 316
  article-title: The development and validation of tau PET tracers: Current status and future directions
  publication-title: Clin. Transl. Imaging
– volume: 415
  start-page: 462
  year: 2002
  end-page: 462
  article-title: Nerve inflammation halts trial for Alzheimer's drug
  publication-title: Nature
– volume: 289
  start-page: 30990
  year: 2014
  end-page: 31000
  article-title: Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein
  publication-title: The Journal of Biological Chemistry
– volume: 402
  start-page: 537
  year: 1999
  end-page: 540
  article-title: Purification and cloning of amyloid precursor protein β‐secretase from human brain
  publication-title: Nature
– volume: 6
  start-page: 144
  year: 2009
  end-page: 151
  article-title: Long‐term follow‐up of patients immunized with AN1792: Reduced functional decline in antibody responders
  publication-title: Current Alzheimer Research
– volume: 120
  start-page: 71
  year: 2012
  end-page: 83
  article-title: Developing β‐secretase inhibitors for treatment of Alzheimer's disease
  publication-title: Journal of Neurochemistry
– volume: 58
  start-page: 681
  year: 2008
  end-page: 693
  article-title: ApoE promotes the proteolytic degradation of Aβ
  publication-title: Neuron
– volume: 3
  start-page: 8
  year: 2012
  article-title: The membrane‐bound aspartyl protease BACE1: Molecular and functional properties in Alzheimer's disease and beyond
  publication-title: Frontiers in Physiology
– volume: 4
  start-page: 195
  year: 2018
  end-page: 214
  article-title: Alzheimer's disease drug development pipeline: 2018
  publication-title: Alzheimer's & Dementia: Translational Research & Clinical Interventions
– volume: 6
  start-page: 228fs13
  year: 2014
  end-page: 228fs13
  article-title: The A4 study: Stopping AD before symptoms begin?
  publication-title: Science Translational Medicine
– start-page: CD003154
  year: 2006
  article-title: Memantine for dementia
  publication-title: Cochrane Database of Systematic Reviews
– volume: 5
  start-page: 160
  year: 2006
  end-page: 170
  article-title: Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
  publication-title: Nature Reviews. Drug Discovery
– volume: 9
  start-page: 95
  year: 2017
  article-title: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
  publication-title: Alzheimer's Research & Therapy
– volume: 72
  start-page: 1858
  year: 1975
  end-page: 1862
  article-title: A protein factor essential for microtubule assembly
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 23
  start-page: 1018
  year: 2017
  end-page: 1027
  article-title: Microglia emerge as central players in brain disease
  publication-title: Nature Medicine
– volume: 58
  start-page: 631
  year: 2017
  end-page: 659
  article-title: State of play in Alzheimer's disease genetics
  publication-title: Journal of Alzheimer's Disease
– volume: 71
  start-page: 362
  year: 2012
  end-page: 381
  article-title: Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature
  publication-title: Journal of Neuropathology and Experimental Neurology
– volume: 99
  start-page: 6364
  year: 2002
  end-page: 6369
  article-title: Tau is essential to β‐amyloid‐induced neurotoxicity
  publication-title: Proceedings of the National Academy of Sciences
– volume: 66
  start-page: 137
  year: 1999
  end-page: 147
  article-title: The cholinergic hypothesis of Alzheimer's disease: A review of progress
  publication-title: Journal of Neurology, Neurosurgery, and Psychiatry
– volume: 246
  start-page: 6
  year: 1999
  end-page: 15
  article-title: Early diagnosis of dementia: Neuropsychology
  publication-title: Journal of Neurology
– volume: 20
  start-page: 2576
  year: 2006
  end-page: 2578
  article-title: Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
  publication-title: The FASEB Journal
– year: 2016
– volume: 97
  start-page: 1456
  year: 2000
  end-page: 1460
  article-title: Human aspartic protease memapsin 2 cleaves the β‐secretase site of β‐amyloid precursor protein
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 38
  start-page: 797
  year: 1995
  end-page: 808
  article-title: Apolipoprotein E genotype in patients with Alzheimer's disease: Implications for the risk of dementia among relatives
  publication-title: Annals of Neurology
– year: 2018d
– volume: 15
  start-page: 73
  year: 2015
  end-page: 82
  article-title: A pivotal moment in Alzheimer's disease and dementia: How global unity of purpose and action can beat the disease by 2025
  publication-title: Expert Review of Neurotherapeutics
– volume: 261
  start-page: 921
  year: 1993
  end-page: 923
  article-title: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
  publication-title: Science
– volume: 4
  start-page: 64
  year: 2018
  end-page: 75
  article-title: Measuring cognition and function in the preclinical stage of Alzheimer's disease
  publication-title: Alzheimer's & Dementia: Translational Research & Clinical Interventions
– volume: 11
  start-page: 241
  year: 2012
  end-page: 249
  article-title: Amyloid‐related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis
  publication-title: Lancet Neurology
– volume: 16
  start-page: 109
  year: 2015
  end-page: 120
  article-title: Spreading of pathology in neurodegenerative diseases: A focus on human studies
  publication-title: Nature Reviews. Neuroscience
– volume: 12
  start-page: 110
  year: 2016
  end-page: 120
  article-title: Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
  publication-title: Alzheimer's Dement.
– volume: 110
  start-page: 9535
  year: 2013
  end-page: 9540
  article-title: Brain homogenates from human tauopathies induce tau inclusions in mouse brain
  publication-title: Proceedings of the National Academy of Sciences
– volume: 59
  start-page: 7389
  year: 2016
  end-page: 7409
  article-title: Gamma secretase modulators: New Alzheimer's drugs on the horizon?
  publication-title: Journal of Medicinal Chemistry
– volume: 170
  start-page: 443
  year: 2017
  end-page: 456.e14
  article-title: Alzheimer's‐causing mutations shift Aβ length by destabilizing γ‐secretase‐Aβn interactions
  publication-title: Cell
– volume: 174
  start-page: S130
  issue: S1
  year: 2017
  end-page: S159
  article-title: The Concise Guide to PHARMACOLOGY 2017/18: Ligand‐gated ion channels
  publication-title: British Journal of Pharmacology
– volume: 58
  start-page: 430
  year: 2005
  end-page: 435
  article-title: Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies
  publication-title: Annals of Neurology
– volume: 16
  start-page: 5795
  year: 1996
  end-page: 5811
  article-title: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β‐amyloid precursor protein and Alzheimer's disease
  publication-title: The Journal of Neuroscience
– volume: 11
  start-page: 1110
  year: 2015
  end-page: 1120
  article-title: Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions
  publication-title: Alzheimer's & Dementia
– volume: 55
  start-page: 1959
  year: 2014
  end-page: 1965
  article-title: 18F‐FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias
  publication-title: Journal of Nuclear Medicine
– volume: 369
  start-page: 341
  year: 2013
  end-page: 350
  article-title: A phase 3 trial of semagacestat for treatment of Alzheimer's disease
  publication-title: The New England Journal of Medicine
– volume: 549
  start-page: 523
  year: 2017
  end-page: 527
  article-title: ApoE4 markedly exacerbates tau‐mediated neurodegeneration in a mouse model of tauopathy
  publication-title: Nature
– volume: 215
  start-page: 1237
  year: 1982
  end-page: 1239
  article-title: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
  publication-title: Science
– year: 2018e
– volume: 53
  start-page: 101
  year: 2014
  end-page: 145
  article-title: γ‐Secretase modulators
  publication-title: Progress in medicinal chemistry
– volume: 68
  start-page: 270
  year: 2010
  end-page: 281
  article-title: The genetics of Alzheimer disease: Back to the future
  publication-title: Neuron
– volume: 402
  start-page: 533
  year: 1999
  end-page: 537
  article-title: Membrane‐anchored aspartyl protease with Alzheimer's disease β‐secretase activity
  publication-title: Nature
– volume: 18
  start-page: 853
  year: 2001
  end-page: 862
  article-title: Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: Epidemiology and management
  publication-title: Drugs & Aging
– volume: 17
  start-page: 79
  year: 2003
  end-page: 81
  article-title: γ‐Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila
  publication-title: The FASEB Journal
– volume: 169
  start-page: 737
  year: 2013
  end-page: 743
  article-title: Preclinical trials in autosomal dominant AD: Implementation of the DIAN‐TU trial
  publication-title: Revue Neurologique (Paris)
– volume: 30
  start-page: 4833
  year: 2010
  end-page: 4844
  article-title: The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex
  publication-title: The Journal of Neuroscience
– volume: 3
  start-page: 425
  year: 2004
  end-page: 440
  article-title: The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
  publication-title: Expert Opinion on Drug Safety
– volume: 13
  start-page: 841
  year: 2017
  end-page: 849
  article-title: Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
  publication-title: Alzheimer's Dement.
– volume: 370
  start-page: 311
  year: 2014
  end-page: 321
  article-title: Phase 3 trials of solanezumab for mild‐to‐moderate Alzheimer's disease
  publication-title: The New England Journal of Medicine
– volume: 71
  start-page: 266
  year: 2012
  end-page: 273
  article-title: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
  publication-title: Journal of Neuropathology and Experimental Neurology
– year: 2018
– volume: 16
  start-page: 55
  year: 2017
  end-page: 65
  article-title: Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis
  publication-title: Lancet Neurology
– volume: 7
  start-page: 180
  year: 1994
  end-page: 184
  article-title: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
  publication-title: Nature Genetics
– volume: 278
  start-page: 1349
  year: 1997
  end-page: 1356
  article-title: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta‐analysis
  publication-title: Jama
– volume: 136
  start-page: 449
  year: 2018
  end-page: 458
  article-title: Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases
  publication-title: Neuropharmacology
– year: 2018b
– volume: 11
  start-page: 909
  year: 2009
  end-page: 913
  article-title: Transmission and spreading of tauopathy in transgenic mouse brain
  publication-title: Nature Cell Biology
– volume: 3
  start-page: 281
  year: 2002
  end-page: 290
  article-title: γ‐Secretase, Notch, Aβ and Alzheimer's disease: Where do the presenilins fit in?
  publication-title: Nature Reviews. Neuroscience
– volume: 377
  start-page: 1019
  year: 2011
  end-page: 1031
  article-title: Alzheimer's disease
  publication-title: Lancet
– volume: 90
  start-page: e1889
  year: 2018
  end-page: e1897
  article-title: ABBY
  publication-title: Neurology
– volume: 155
  start-page: S33
  issue: Suppl 4
  year: 1999
  end-page: S37
  article-title: Diagnosis of early Alzheimer's disease
  publication-title: Revue Neurologique (Paris)
– volume: 11
  start-page: 155
  year: 2010
  end-page: 159
  article-title: Prion‐like mechanisms in neurodegenerative diseases
  publication-title: Nature Reviews. Neuroscience
– volume: 80
  start-page: 254
  year: 2013
  end-page: 256
  article-title: Anti‐tau antibodies: Hitting the target
  publication-title: Neuron
– volume: 60
  start-page: 1696
  year: 2003
  article-title: Cerebrospinal fluid tau and β‐amyloid
  publication-title: Archives of Neurology
– volume: 375
  start-page: 754
  year: 1995
  end-page: 760
  article-title: Cloning of a gene bearing missense mutations in early‐onset familial Alzheimer's disease
  publication-title: Nature
– volume: 69
  start-page: 198
  year: 2012
  end-page: 207
  article-title: Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
  publication-title: Archives of Neurology
– volume: 2
  start-page: a006312
  year: 2012
  article-title: Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease
  publication-title: Cold Spring Harbor Perspectives in Medicine
– volume: 9
  start-page: 438
  year: 2013
  end-page: 444
  article-title: Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force
  publication-title: Alzheimer's & Dementia
– volume: 9
  start-page: 448
  year: 2003
  end-page: 452
  article-title: Neuropathology of human Alzheimer disease after immunization with amyloid‐β peptide: A case report
  publication-title: Nature Medicine
– year: 2015
– volume: 95
  start-page: 7737
  year: 1998
  end-page: 7741
  article-title: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
– volume: 11
  start-page: 205
  year: 1970
  end-page: 242
  article-title: Observations on the brains of demented old people
  publication-title: Journal of the Neurological Sciences
– volume: 3
  start-page: 320
  year: 2013
  end-page: 332
  article-title: Rate of conversion from prodromal Alzheimer's disease to Alzheimer's dementia: A systematic review of the literature
  publication-title: Dementia and Geriatric Cognitive Disorders Extra
– year: 2018c
– volume: 286
  start-page: 735
  year: 1999
  end-page: 741
  article-title: β‐Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
  publication-title: Science
– volume: 41
  start-page: 24
  year: 2015
  end-page: 46
  article-title: Invited review: Frontotemporal dementia caused by gene ( ) mutations: A chameleon for neuropathology and neuroimaging
  publication-title: Neuropathology and Applied Neurobiology
– volume: 349
  start-page: 704
  year: 1991
  end-page: 706
  article-title: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
  publication-title: Nature
– volume: 2
  start-page: 1403
  year: 1976
  article-title: Selective loss of central cholinergic neurons in Alzheimer's disease
  publication-title: Lancet (London, England)
– volume: 174
  start-page: S1
  issue: S1
  year: 2017
  end-page: S16
  article-title: The Concise Guide to PHARMACOLOGY 2017/18: Overview
  publication-title: British Journal of Pharmacology
– volume: 9
  start-page: 625
  year: 2018
  article-title: In vivo imaging of glial activation in Alzheimer's disease
  publication-title: Frontiers in Neurology
– volume: 370
  start-page: 1459
  year: 2014
  end-page: 1460
  article-title: Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease
  publication-title: The New England Journal of Medicine
– volume: 55
  start-page: 937
  year: 1998
  end-page: 945
  article-title: High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein
  publication-title: E genotype. Arch. Neurol.
– volume: 8
  start-page: 363ra150
  year: 2016
  end-page: 363ra150
  article-title: The BACE1 inhibitor verubecestat (MK‐8931) reduces CNS β‐amyloid in animal models and in Alzheimers disease patients
  publication-title: Science Translational Medicine
– volume: 297
  start-page: 353
  year: 2002
  end-page: 356
  article-title: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
  publication-title: Science (80‐.).
– volume: 164
  start-page: 603
  year: 2016
  end-page: 615
  article-title: The cellular phase of Alzheimer's disease
  publication-title: Cell
– volume: 29
  start-page: 3020
  year: 2010
  end-page: 3032
  article-title: ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons
  publication-title: The EMBO Journal
– volume: 14
  start-page: 2313
  year: 1994
  end-page: 2326
  article-title: AMPA‐induced excitotoxic lesions of the basal forebrain: A significant role for the cortical cholinergic system in attentional function
  publication-title: The Journal of Neuroscience
– volume: 46
  start-page: D1091
  year: 2018
  end-page: D1106
  article-title: The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
  publication-title: Nucl Acids Res
– volume: 49
  start-page: 1373
  year: 2017
  end-page: 1384
  article-title: Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial‐mediated innate immunity in Alzheimer's disease
  publication-title: Nature Genetics
– volume: 7
  start-page: a024539
  year: 2017
  article-title: Genetics of β‐amyloid precursor protein in Alzheimer's disease
  publication-title: Cold Spring Harbor Perspectives in Medicine
– volume: 42
  start-page: 631
  year: 1992
  end-page: 639
  article-title: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
  publication-title: Neurology
– volume: 2
  start-page: 356
  year: 2013
  end-page: 365
  article-title: Amyloid imaging in cognitively normal individuals, at‐risk populations and preclinical Alzheimer's disease
  publication-title: NeuroImage: Clinical
– volume: 12
  start-page: 292
  year: 2016
  end-page: 323
  article-title: Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
  publication-title: Alzheimer's Dement.
– volume: 2
  start-page: 357
  year: 1984
  end-page: 369
  article-title: The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis
  publication-title: Applied Pathology
– volume: 80
  start-page: 1347
  year: 2013
  end-page: 1358
  article-title: Biomarker modeling of Alzheimer's disease
  publication-title: Neuron
– volume: 9
  start-page: 161
  year: 2017
  article-title: Novel insights into the physiological function of the APP (gene) family and its proteolytic fragments in synaptic plasticity
  publication-title: Frontiers in Molecular Neuroscience
– volume: 14
  start-page: 419
  year: 1999
  end-page: 427
  article-title: Identification of a novel aspartic protease (Asp 2) as β‐secretase
  publication-title: Molecular and Cellular Neuroscience
– volume: 69
  start-page: 1471
  year: 2001
  end-page: 1484
  article-title: Uncharged thioflavin‐T derivatives bind to amyloid‐beta protein with high affinity and readily enter the brain
  publication-title: Life Sciences
– year: 2006
– volume: 12
  start-page: 383
  year: 1991
  end-page: 388
  article-title: Amyloid deposition as the central event in the aetiology of Alzheimer's disease
  publication-title: Trends in Pharmacological Sciences
– volume: 277
  start-page: 825
  year: 1997
  end-page: 831
  article-title: Exploring the etiology of Alzheimer disease using molecular genetics
  publication-title: Jama
– volume: 64
  start-page: 492
  year: 2008
  end-page: 498
  article-title: Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms
  publication-title: Annals of Neurology
– volume: 138
  start-page: 1134
  year: 2015
  end-page: 1137
  article-title: New criteria for Alzheimer's disease: Which, when and why?
  publication-title: Brain
– volume: 378
  start-page: 321
  year: 2018
  end-page: 330
  article-title: Trial of solanezumab for mild dementia due to Alzheimer's disease
  publication-title: The New England Journal of Medicine
– volume: 59
  start-page: 10435
  year: 2016
  end-page: 10450
  article-title: Discovery of the 3‐imino‐1,2,4‐thiadiazinane 1,1‐dioxide derivative verubecestat (MK‐8931)—A β‐site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's disease
  publication-title: Journal of Medicinal Chemistry
– volume: 488
  start-page: 96
  year: 2012
  end-page: 99
  article-title: A mutation in APP protects against Alzheimer's disease and age‐related cognitive decline
  publication-title: Nature
– volume: 537
  start-page: 50
  year: 2016
  end-page: 56
  article-title: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
  publication-title: Nature
– volume: 134
  start-page: 187
  year: 2017
  end-page: 205
  article-title: Interactions of pathological proteins in neurodegenerative diseases
  publication-title: Acta Neuropathologica
– ident: e_1_2_8_33_1
  doi: 10.1016/j.trci.2018.03.009
– ident: e_1_2_8_53_1
  doi: 10.1016/S1474-4422(03)00530-1
– ident: e_1_2_8_100_1
  doi: 10.1097/NEN.0b013e31825018f7
– ident: e_1_2_8_81_1
  doi: 10.1038/nrd3505
– ident: e_1_2_8_135_1
  doi: 10.1016/j.cell.2017.07.004
– ident: e_1_2_8_46_1
  doi: 10.1002/ana.410380515
– ident: e_1_2_8_111_1
– ident: e_1_2_8_138_1
  doi: 10.1016/0022-510X(70)90063-8
– ident: e_1_2_8_145_1
  doi: 10.1159/000354370
– ident: e_1_2_8_108_1
  doi: 10.1586/14737175.2014.945522
– ident: e_1_2_8_87_1
  doi: 10.1096/fj.06-6463fje
– ident: e_1_2_8_73_1
  doi: 10.1038/31508
– ident: e_1_2_8_51_1
  doi: 10.1136/jnnp.66.2.137
– ident: e_1_2_8_113_1
  doi: 10.1038/nrneurol.2015.177
– ident: e_1_2_8_32_1
  doi: 10.1038/ng0694-180
– ident: e_1_2_8_88_1
  doi: 10.1073/pnas.97.4.1456
– ident: e_1_2_8_10_1
– ident: e_1_2_8_29_1
  doi: 10.1073/pnas.1301175110
– ident: e_1_2_8_38_1
  doi: 10.3389/fphys.2012.00008
– ident: e_1_2_8_48_1
  doi: 10.1016/j.neuropharm.2018.01.028
– ident: e_1_2_8_106_1
  doi: 10.1186/s13195-017-0318-y
– ident: e_1_2_8_2_1
  doi: 10.1186/s13195-017-0283-5
– ident: e_1_2_8_25_1
  doi: 10.1038/emboj.2012.79
– ident: e_1_2_8_59_1
  doi: 10.1038/349704a0
– ident: e_1_2_8_9_1
– ident: e_1_2_8_26_1
  doi: 10.1038/415462a
– ident: e_1_2_8_132_1
  doi: 10.1073/pnas.95.13.7737
– ident: e_1_2_8_27_1
  doi: 10.1016/j.nicl.2013.02.006
– ident: e_1_2_8_147_1
  doi: 10.1073/pnas.72.5.1858
– ident: e_1_2_8_122_1
  doi: 10.1038/nature19323
– ident: e_1_2_8_124_1
  doi: 10.1038/nature24016
– ident: e_1_2_8_45_1
  doi: 10.1056/NEJMoa1706441
– ident: e_1_2_8_115_1
  doi: 10.1212/WNL.0000000000000596
– ident: e_1_2_8_85_1
  doi: 10.1002/ana.20592
– ident: e_1_2_8_152_1
  doi: 10.1038/990107
– ident: e_1_2_8_66_1
  doi: 10.1016/0165-6147(91)90609-V
– ident: e_1_2_8_17_1
  doi: 10.1016/S0196-9781(02)00261-9
– ident: e_1_2_8_60_1
  doi: 10.1016/j.neuron.2013.10.009
– volume: 95
  start-page: 229
  year: 1985
  ident: e_1_2_8_23_1
  article-title: Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer
  publication-title: Archives of Biology (Liege)
– ident: e_1_2_8_65_1
  doi: 10.1093/nar/gkx1121
– ident: e_1_2_8_64_1
  doi: 10.1016/B978-0-444-63380-4.00003-2
– ident: e_1_2_8_68_1
  doi: 10.1016/S0140-6736(08)61075-2
– ident: e_1_2_8_148_1
  doi: 10.1016/j.trci.2018.01.003
– ident: e_1_2_8_7_1
– ident: e_1_2_8_37_1
  doi: 10.1038/nrneurol.2009.218
– ident: e_1_2_8_52_1
  doi: 10.1038/nrn2786
– ident: e_1_2_8_39_1
  doi: 10.1056/NEJMoa1312889
– ident: e_1_2_8_4_1
  doi: 10.1111/bph.13877
– ident: e_1_2_8_117_1
  doi: 10.1056/NEJMoa1304839
– ident: e_1_2_8_127_1
  doi: 10.1038/990114
– ident: e_1_2_8_42_1
  doi: 10.1016/j.jalz.2016.02.002
– ident: e_1_2_8_30_1
  doi: 10.1038/ncb1901
– ident: e_1_2_8_34_1
  doi: 10.1212/WNL.0000000000005550
– ident: e_1_2_8_13_1
  doi: 10.1212/WNL.42.3.631
– ident: e_1_2_8_125_1
  doi: 10.1016/j.jalz.2015.06.1893
– ident: e_1_2_8_142_1
  doi: 10.2174/156720509787602852
– ident: e_1_2_8_21_1
  doi: 10.1111/joim.12816
– start-page: CD003154
  year: 2006
  ident: e_1_2_8_94_1
  article-title: Memantine for dementia
  publication-title: Cochrane Database of Systematic Reviews
– ident: e_1_2_8_3_1
  doi: 10.1111/bph.13878
– ident: e_1_2_8_5_1
  doi: 10.1111/bph.13882
– ident: e_1_2_8_16_1
  doi: 10.1016/S0140-6736(10)61349-9
– ident: e_1_2_8_86_1
  doi: 10.1001/jama.1997.03540340059034
– ident: e_1_2_8_120_1
  doi: 10.1093/brain/awv055
– ident: e_1_2_8_91_1
  doi: 10.1074/jbc.M114.589069
– ident: e_1_2_8_92_1
– ident: e_1_2_8_128_1
  doi: 10.1038/nrn785
– ident: e_1_2_8_49_1
  doi: 10.1016/S0140-6736(13)62426-5
– ident: e_1_2_8_56_1
  doi: 10.1111/nan.12213
– ident: e_1_2_8_118_1
  doi: 10.1038/nm.4397
– ident: e_1_2_8_153_1
  doi: 10.3233/JAD-170062
– ident: e_1_2_8_112_1
  doi: 10.1073/pnas.092136199
– ident: e_1_2_8_72_1
  doi: 10.1006/mcne.1999.0811
– volume: 155
  start-page: S33
  issue: 4
  year: 1999
  ident: e_1_2_8_50_1
  article-title: Diagnosis of early Alzheimer's disease
  publication-title: Revue Neurologique (Paris)
– ident: e_1_2_8_134_1
  doi: 10.1073/pnas.90.5.1977
– ident: e_1_2_8_61_1
  doi: 10.1016/j.pneurobio.2007.02.001
– ident: e_1_2_8_103_1
– ident: e_1_2_8_71_1
  doi: 10.1056/NEJMoa1705971
– ident: e_1_2_8_123_1
  doi: 10.1038/375754a0
– ident: e_1_2_8_151_1
– ident: e_1_2_8_78_1
  doi: 10.1016/j.neuron.2008.04.010
– ident: e_1_2_8_143_1
  doi: 10.1016/j.jalz.2013.03.007
– ident: e_1_2_8_96_1
  doi: 10.1016/j.neurol.2013.07.017
– ident: e_1_2_8_140_1
  doi: 10.1126/science.286.5440.735
– ident: e_1_2_8_150_1
– ident: e_1_2_8_44_1
  doi: 10.3389/fneur.2018.00625
– ident: e_1_2_8_109_1
  doi: 10.1007/s004150050299
– ident: e_1_2_8_55_1
  doi: 10.1093/embo-reports/kvf124
– ident: e_1_2_8_129_1
  doi: 10.1016/j.neuron.2014.10.038
– ident: e_1_2_8_69_1
  doi: 10.1101/cshperspect.a006312
– ident: e_1_2_8_35_1
  doi: 10.1016/S0140-6736(76)91936-X
– ident: e_1_2_8_83_1
  doi: 10.1016/S0024-3205(01)01232-2
– ident: e_1_2_8_22_1
  doi: 10.1038/nrn3887
– volume: 2
  start-page: 357
  year: 1984
  ident: e_1_2_8_58_1
  article-title: The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis
  publication-title: Applied Pathology
– volume: 149
  start-page: 29
  year: 1993
  ident: e_1_2_8_116_1
  article-title: Tetrahydroaminoacridine (THA) in Alzheimer's disease: An assessment of attentional and mnemonic function using CANTAB
  publication-title: Acta Neurologica Scandinavica. Supplementum
– ident: e_1_2_8_67_1
  doi: 10.1126/science.1072994
– ident: e_1_2_8_131_1
  doi: 10.1126/scitranslmed.3007941
– ident: e_1_2_8_77_1
  doi: 10.1093/brain/awq277
– ident: e_1_2_8_57_1
  doi: 10.1111/j.1471-4159.2011.07476.x
– ident: e_1_2_8_31_1
  doi: 10.1126/science.8346443
– ident: e_1_2_8_82_1
  doi: 10.1126/scitranslmed.aad9704
– ident: e_1_2_8_80_1
  doi: 10.1523/JNEUROSCI.5221-09.2010
– ident: e_1_2_8_99_1
  doi: 10.1038/nature25456
– ident: e_1_2_8_15_1
  doi: 10.1038/ng1197-263
– ident: e_1_2_8_76_1
  doi: 10.1016/j.neuron.2013.12.003
– ident: e_1_2_8_121_1
  doi: 10.1021/acs.jmedchem.6b00307
– ident: e_1_2_8_136_1
  doi: 10.1101/cshperspect.a024539
– ident: e_1_2_8_84_1
  doi: 10.1038/emboj.2010.167
– ident: e_1_2_8_75_1
  doi: 10.1016/S1474-4422(16)30291-5
– ident: e_1_2_8_133_1
  doi: 10.1007/s00401-017-1709-7
– ident: e_1_2_8_146_1
  doi: 10.1016/j.jalz.2010.03.007
– ident: e_1_2_8_28_1
  doi: 10.1001/archneur.60.12.1696
– ident: e_1_2_8_54_1
  doi: 10.2165/00002512-200118110-00006
– ident: e_1_2_8_102_1
  doi: 10.2967/jnumed.114.143347
– ident: e_1_2_8_119_1
  doi: 10.1038/22124
– ident: e_1_2_8_11_1
– ident: e_1_2_8_89_1
  doi: 10.1038/nrd1958
– ident: e_1_2_8_18_1
  doi: 10.1097/NEN.0b013e31824b211b
– ident: e_1_2_8_6_1
  doi: 10.1111/bph.13879
– ident: e_1_2_8_90_1
  doi: 10.3389/fnmol.2016.00161
– ident: e_1_2_8_14_1
  doi: 10.1186/s12916-014-0206-2
– ident: e_1_2_8_47_1
  doi: 10.1001/jama.1997.03550160069041
– ident: e_1_2_8_97_1
  doi: 10.1007/s00259-015-3228-x
– ident: e_1_2_8_41_1
  doi: 10.1056/NEJMoa1312889
– ident: e_1_2_8_137_1
  doi: 10.1517/14740338.3.5.425
– ident: e_1_2_8_24_1
  doi: 10.1021/acs.jmedchem.5b01960
– ident: e_1_2_8_36_1
  doi: 10.1016/j.cell.2015.12.056
– ident: e_1_2_8_101_1
  doi: 10.1038/nm840
– ident: e_1_2_8_19_1
  doi: 10.1016/j.neuron.2010.10.013
– ident: e_1_2_8_149_1
  doi: 10.1126/science.7058341
– ident: e_1_2_8_95_1
  doi: 10.1096/fj.02-0394fje
– ident: e_1_2_8_12_1
  doi: 10.1002/ana.21509
– ident: e_1_2_8_105_1
  doi: 10.1001/archneurol.2011.1538
– ident: e_1_2_8_70_1
  doi: 10.1126/science.290.5489.150
– ident: e_1_2_8_107_1
  doi: 10.1016/j.jalz.2017.06.2266
– ident: e_1_2_8_110_1
  doi: 10.2174/1573406413666171002120847
– ident: e_1_2_8_114_1
  doi: 10.1016/j.ejrad.2017.07.014
– ident: e_1_2_8_62_1
  doi: 10.1016/S0021-9258(17)38495-8
– ident: e_1_2_8_141_1
  doi: 10.1111/jnc.12715
– ident: e_1_2_8_8_1
– ident: e_1_2_8_20_1
  doi: 10.1002/14651858.CD005593
– ident: e_1_2_8_79_1
  doi: 10.1038/nature11283
– ident: e_1_2_8_43_1
  doi: 10.1016/j.biopsych.2017.08.010
– ident: e_1_2_8_139_1
  doi: 10.1016/j.jalz.2014.08.105
– ident: e_1_2_8_98_1
  doi: 10.1523/JNEUROSCI.14-04-02313.1994
– ident: e_1_2_8_144_1
  doi: 10.1586/14737175.2015.995638
– ident: e_1_2_8_104_1
  doi: 10.1007/s40336-018-0290-y
– ident: e_1_2_8_40_1
  doi: 10.1056/NEJMoa1210951
– ident: e_1_2_8_74_1
  doi: 10.1016/S0140-6736(86)92134-3
– ident: e_1_2_8_63_1
  doi: 10.1007/s13311-014-0295-9
– ident: e_1_2_8_93_1
  doi: 10.1523/JNEUROSCI.16-18-05795.1996
– ident: e_1_2_8_126_1
  doi: 10.1038/ng.3916
– ident: e_1_2_8_130_1
  doi: 10.1016/S1474-4422(12)70015-7
SSID ssj0014775
Score 2.4077373
SecondaryResourceType review_article
Snippet Globally, there are approximately 47 million people living with dementia, and about two thirds of those have Alzheimer's disease (AD). Age is the single...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3636
SubjectTerms Aging
Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Alzheimer's disease
Amyloid beta-Peptides - metabolism
Animals
Dementia
Dementia disorders
Humans
Neurodegenerative diseases
Precision medicine
Review
Risk factors
Themed Section: Review
Title A short perspective on the long road to effective treatments for Alzheimer's disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbph.14581
https://www.ncbi.nlm.nih.gov/pubmed/30657599
https://www.proquest.com/docview/2296298347
https://www.proquest.com/docview/2179380563
https://pubmed.ncbi.nlm.nih.gov/PMC6715596
Volume 176
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZZC6MvY7-brRvaGN0gdYllW7Ifk24lDDrClkLfPEmWSSGzw5w8tH_9TpIt22sLW1-MsYRl6_t0upNOdwh9SEgWsJxIj0c89EKRZx5oGZknk0CxRAiSmFPvZ9_o7Dz8ehFdDAY_O15L2404lte3niu5D6rwDHDVp2T_A1n3UngA94AvXAFhuP4TxpNRtQT1Wccebk5M1ov_o5XJIVTyTCuX1mlDlzq_chOGYTRZXS_VpUmgwqreZs1fMY86ASbWbbBrtxz_XV0V5SqrnJf86Mdxdz3Bbx2malnfOuxY39Gi6rtkaq3CA7PESk1lxWbIqAei0-_JVZvYpSFQ3BGTAQ1oZ8oNqI22eYc4F-slCPTIvr0D6_qXwRWMHp1lNGlnNOdnOD87oUxvvNIHaJeAIQGScHcy_Tw9dTtNIWM2y0X9V3X0Ke3t5drdQw-bRvrqyw2b5KZrbdfkMTrL4jF6VBsbeGKZ8wQNVPEUHc4tgFdHeNEevquO8CGed6B9hhYTbOiFO_TCZYGBXljTC2t64U2JHb1wSy8M9MKOXh8rXJPrOTo__bI4mXl1Eg5PhqBceoJAB3BKFKUs4TShXEgQ5BI60xdszOOISsF97ke5IiTOKRFxGMk8GEvBlAyDF2inKAu1jzDl_lgmjJM80qsQGbwr8GmeKZ5TmAqyIfrU9G0q6wj1OlHKKm0sVUAkNYgM0XtXdW3DstxW6aABKK2HSZUSkD4kiYOQDdE7VwwyVW-U8UKVW6ijZ60YTINgiF5aPF0rDRGGiPWQdhV0vPZ-SXG5NHHbayrCbxpO3P3h6XQ-Mzev7t3Ia7TXDu4DtLP5vVVvQH3eiLf1CPgD9qvITg
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+short+perspective+on+the+long+road+to+effective+treatments+for+Alzheimer%27s+disease&rft.jtitle=British+journal+of+pharmacology&rft.au=Reynolds%2C+David+S.&rft.date=2019-09-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=0007-1188&rft.eissn=1476-5381&rft.volume=176&rft.issue=18&rft.spage=3636&rft.epage=3648&rft_id=info:doi/10.1111%2Fbph.14581&rft_id=info%3Apmid%2F30657599&rft.externalDocID=PMC6715596
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon